Jecho Biopharmaceuticals Co., Ltd.

This early-stage study tested the safety of a single injection called JL15003 in adults whose aggressive brain cancer (glioblastoma) had returned after standard treatment. The main goal was to find the highest dose patients could tolerate without severe side effects. Researchers …

This study tested if a new eye injection called JL14002 works as well as the standard treatment (ranibizumab/Lucentis) for wet age-related macular degeneration, a leading cause of vision loss in older adults. 443 patients received either the new injection or the standard one ever…